Daridorexant 25 mg + Daridorexant 50 mg
Phase 3Completed 0 watching 0 views this week๐ Rising
72
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Insomnia Disorder
Conditions
Insomnia Disorder
Trial Timeline
Jun 4, 2018 โ Feb 25, 2020
NCT ID
NCT03545191About Daridorexant 25 mg + Daridorexant 50 mg
Daridorexant 25 mg + Daridorexant 50 mg is a phase 3 stage product being developed by Idorsia for Insomnia Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT03545191. Target conditions include Insomnia Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03545191 | Phase 3 | Completed |
Competing Products
20 competing products in Insomnia Disorder